EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Abstract Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of EGFR tyrosine kinase inhibitors (TKIs) marked the beginning of the targeted therapy era for non-small-cell lu...

Full description

Bibliographic Details
Main Authors: Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang, Qiming Wang
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Biomarker Research
Subjects:
Lung cancer
EGFR exon 20 insertion mutations
Tyrosine kinase inhibitor
Immune checkpoint inhibitor
Online Access:https://doi.org/10.1186/s40364-022-00372-6

Internet

https://doi.org/10.1186/s40364-022-00372-6

Similar Items